All In Biotech

Drug Trial Radar · NCT06682169

Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

A Randomized, Open Label, Positive Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of the Selected Regimen of Rovadicitinib in Moderate to Severe Chronic Graft-versus-host Disease in Third Line and Beyond

Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

182

Planned (sponsor's estimate)

Start

Nov 20, 2024

Primary completion

Oct 2029

Study completion Dec 2030

Sponsor

Sponsor type
Industry
First posted
Nov 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to demonstrate that in subjects with moderate to severe chronic graft-versus-host disease in the third line and beyond, the use of rosuvastatin compared to the protocol chosen by the researchers can significantly improve the objective response rate of subjects at week 24.

Conditions

  • Graft-versus-host Disease

Interventions

  • RovadicitinibDrug

    Rovadicitinib is an inhibitor of Janus associated kinases (JAK) family and Rho associated kinases (ROCK). It can inhibit the sustained abnormal activation of the Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway and also inhibit Rho associated kinase 2 (ROCK2). The JAK 1-JAK 2 signaling pathway is a key step in causing inflammation and tissue damage in acute and chronic graft-versus-host disease.

  • ImatinibDrug

    Imatinib tyrosine kinase inhibitor is a small molecule protein kinase inhibitor that has the ability to block one or more protein kinases. Clinically used for the treatment of chronic myeloid leukemia and malignant gastrointestinal stromal tumors.

  • MethotrexateDrug

    Methotrexate is an organic compound, mainly used as an anti folate anti-tumor drug. It inhibits the synthesis of tumor cells by inhibiting dihydrofolate reductase, thereby inhibiting the growth and reproduction of tumor cells.

  • Mycophenolate mofetilDrug

    Metoprolol ester is an organic compound mainly used as an immunosuppressant

  • RituximabDrug

    Rituximab activates antibody dependent cell-mediated phagocytosis and complement dependent cytotoxicity by binding to cluster of differentiation 20 (CD20) antigen, clearing malignant B cells expressing CD20 and achieving therapeutic goals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective remission rate in the 24th week (ORR)Time frame: Week 24

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of USTC Anhui Provincial Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The Southwest Hospital of AMU

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Not yet recruiting

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China · Not yet recruiting

  • The 904 Hospital of the Joint Service Support Force of the People's Liberation Army of China

    Lanzhou, Gansu, China · Not yet recruiting

  • Guangzhou First People's Hospital The First People's Hospital Affiliated to Guangzhou Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Nanfang Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Not yet recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Not yet recruiting

  • The Second Hospital of Hebei Medical Hospital

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • The Third People's Hospital of Zhengzhou

    Zhengzhou, Henan, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhenzhou, Henan, China · Recruiting

  • Wuhan Union Hospital of China

    Wuhan, Hubei, China · Not yet recruiting

  • Tongji Hospital Tongji Medical College of HUST

    Wuhan, Hubei, China · Not yet recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Huai'an Second People's Hospital

    Huai'an, Jiangsu, China · Not yet recruiting

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China · Not yet recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • First Hospital of Jilin University

    Changchun, Jilin, China · Not yet recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Not yet recruiting

  • Tai'an City Central Hospital

    Tai’an, Shandong, China · Not yet recruiting

  • Shanghai Jiao Tong University School of Medicine,Renji Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Ruijin Hospital, Shanghai Jiaotong University School Of Medicine

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China · Not yet recruiting

  • Shanxi Provincial People's Hospital

    Xi’an, Shanxi, China · Not yet recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Chinese Academy of Medical Sciences Hematology Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • The First Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China · Not yet recruiting

  • The First People's Hospital of Yunnan Province

    Kunming, Yunnan, China · Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • The Affiliated People's Hospital of Ningbo University

    Ningbo, Zhejiang, China · Not yet recruiting

  • The First Affiliated Hospital of Ningbo University

    Ningbo, Zhejiang, China · Not yet recruiting

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.